Sucampo Announces Departure of Chief Financial Officer

Sucampo Announces Departure of Chief Financial Officer

BETHESDA, Md., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Sucampo
Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that Cary J. Claiborne,
Chief Financial Officer (CFO), is leaving Sucampo to pursue other
interests. Mr. Claiborne will continue in his current role through
November 7, 2014, and Sucampo has initiated a search for a new CFO.

"The Board and I would like to thank Cary for the contributions he has
made to Sucampo during his tenure as CFO, and we wish him the very best
in his future endeavors," said Peter Greenleaf, Chief Executive Officer
of Sucampo. "Our focus today is solidly on executing the strategy we
have defined to drive the next evolution of Sucampo and on
accomplishing the ambitious goals we have set for ourselves to drive
increased shareholder and patient value: strengthening our
organizational capabilities and leadership team, securing our revenue
from AMITIZA in the U.S. and globally, focusing our scientific
investments to accelerate our pipeline, and diversifying our science."

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the development and
commercialization of medicines to meet the major unmet medical needs of
patients on a global basis. Sucampo has two marketed products -
AMITIZA(R) and RESCULA(R) - and a pipeline of product candidates in
clinical development. A global company, Sucampo is headquartered in
Bethesda, Maryland, and has operations in Japan, Switzerland and the
U.K. For more information, please visit www.sucampo.com.

The Sucampo logo is the registered trademark and the tagline, The
Science of Innovation, is a pending trademark of Sucampo AG. AMITIZA is
a registered trademark of Sucampo AG. RESCULA is a registered trademark
of R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo
Pharmaceuticals).

Twitter LinkedIn

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term
is defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations and
involve risks and uncertainties, which may cause results to differ
materially from those set forth in the statements. The forward-looking
statements may include statements regarding product development,
product potential, future financial and operating results, and other
statements that are not historical facts. The following factors, among
others, could cause actual results to differ from those set forth in
the forward-looking statements: the impact of pharmaceutical industry
regulation and health care legislation; Sucampo's ability to accurately
predict future market conditions; dependence on the effectiveness of
Sucampo's patents and other protections for innovative products; the
risk of new and changing regulation and health policies in the U.S. and
internationally and the exposure to litigation and/or regulatory
actions. No forward-looking statement can be guaranteed and actual
results may differ materially from those projected. Sucampo undertakes
no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events, or otherwise.
Forward-looking statements in this presentation should be evaluated
together with the many uncertainties that affect Sucampo's business,
particularly those mentioned in the risk factors and cautionary
statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo
incorporates by reference.


CONTACT: Sucampo Pharmaceuticals, Inc.
         Silvia Taylor
         Senior Vice President, Investor Relations
         and Corporate Communications
         1-240-223-3718
         [email protected]
 

Suggested Articles

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.